BioSpecifics Technologies Announces Partnership between Auxilium, Swedish Orphan Biovitrum AB for XIAPEX in Eurasia and Africa

BioSpecifics Technologies Corp.

today announced that its partner Auxilium Pharmaceuticals, Inc.

has entered into a collaboration with Swedish Orphan Biovitrum AB (Sobi) for the long-term development, supply and commercialization of XIAPEX (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture.  Additionally, the process is underway to file for approval of XIAPEX for the treatment of Peyronie's disease in the EU. "We believe this strategic collaboration with Sobi will enable further growth of XIAPEX in the EU and additional regions.  The expanded sales territory now includes a total of 71 countries which will continue the upward momentum of getting this treatment to new audiences. Sobi has a proven track record of commercializing innovative products and we are excited about reaching patients with these unmet medical needs through this collaboration," reflected Thomas L. Wegman, President of BioSpecifics. "We look forward to further news this quarter with the potential approval of XIAFLEX in the U.S. for Peyronie's disease."